Vivoryon Therapeutics N.V. announced the appointment of Dr. Claudia Riedl and Samir Shah, MD, to its Non-Executive Board of Directors. Both appointments were approved during Vivoryon's Annual General Meeting which took place June 22, 2022. Samir Shah, MD, brings extensive senior executive, investor relations, business development, commercial and financial expertise to Vivoryon.

In addition to his current role as Head of Investor Relations for Novartis, a company he has been with since 2004, he is a member of several executive groups and committees within the organization, including Finance Leadership Team, Innovation Management Board and Trust & Reputation Committee. Prior to Novartis, Dr. Shah spent more than 12 years at Merck Serono, where he led several global franchises, including neurology. He graduated as a physician from University of Sheffield, England and joined the pharmaceutical industry after completing his postgraduate medical training (MRCP).

Dr. Shah also holds an MBA from the University of Warwick, England. Dr. Claudia Riedl's broad expertise includes senior advisory roles in a number of IPOs and financings in various geographies. During her more than 15-year tenure as Head of Corporate Communications and Investor Relations at the German biotech MorphoSys until 2016, she supported the company's transformation and growth from a technology-focused antibody discovery and development enterprise into a fully integrated biopharmaceutical company.

Subsequently, in a senior advisor capacity, she was instrumental in the company's successful secondary listing on Nasdaq in 2018. Following an apprenticeship at Deutsche Bank AG, Dr. Riedl studied biology and earned a PhD at Technical University, Munich, Germany.